PD04.05. First-Line Treatment Strategies Considering Quality of Life in Unresectable or Recurrent Esophageal Cancer

Clicks: 21
ID: 326181
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #209 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Non-Surgical Treatment of Esophageal Cancer Background Immune checkpoint inhibitors (ICIs) are established as standard treatments for unresectable or recurrent esophageal cancer. Nevertheless, a substantial proportion of patients experience severe dysphagia and malnutrition, which significantly impairs quality of life. The optimal first-line treatment strategy that addresses both therapeutic efficacy and symptom relief has yet to be determined. Methods From February 2022 to December 2024, 78 patients with unresectable or recurrent esophageal cancer received either ICI plus chemotherapy or dual ICI therapy. Of these, 54 evaluable patients were retrospectively analyzed. Patients presenting with severe dysphagia (dysphagia score [DS] 4) underwent palliative radiotherapy to the primary tumor (25 Gy in 5 fractions) during treatment interruption. In the ICI plus chemotherapy group, a novel first-line approach incorporating palliative radiotherapy for cases with critical esophageal stenosis was implemented. Treatment response, survival outcomes, adverse events, and changes in dysphagia score were assessed. Results In the ICI plus chemotherapy group (n=40; unresectable 19, recurrent 21; median age 67.5 years), the best overall responses included complete response (CR) in 3 patients, partial response (PR) in 15, stable disease (SD) in 9, and progressive disease (PD) in 11. The overall response rate (CR+PR) was 47%, and clinical efficacy (CR+PR+SD) reached 76%. Grade 3 or higher hematologic toxicity was observed in 43%, and immune-related adverse events (irAEs) occurred in 58% (Grade 3 or higher: 8%). Among unresectable cases, 50% achieved at least 20% tumor shrinkage at the first evaluation. Dysphagia improved by two or more grades in 80% of evaluable patients, including 82% of those who received palliative radiotherapy. One- and two-year overall survival rates were 72.7% and 60.7%, respectively. In the dual ICI group (n=15), the overall response rate was 15%, and Grade 3 or higher immune-related adverse events occurred in 40%. Conclusion First-line ICI plus chemotherapy combined with palliative radiotherapy resulted in rapid improvement of dysphagia and favorable clinical outcomes in patients with unresectable or recurrent esophageal cancer. This strategy may offer a valuable treatment option that balances tumor control with preservation of quality of life.
Reference Key
openalex_W7203971194 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Akiyuki Wakita, Yusuke Sato, Yushi Nagaki, Takatoshi Yoneya, Yusuke Minamizuka, Tsukasa Takahashi, Kazuhiro Imai
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.100
URL
https://academic.oup.com/dote/article-pdf/39/Supplement_1/doag077.100/70760497/doag077.100.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.